With the rapid advancement of cell and gene therapies, tumor immunotherapy and regenerative medicine are entering a golden era of clinical translation. On November 19 and 20, the event will feature dedicated sessions including the "Innovative Cell Therapies and Clinical Applications Forum," "Cell Therapy and Regenerative Medicine Forum," "Exosome Technology and Translational Applications Forum," and "Stem Cells and Regenerative Medicine Forum."
The agenda comprehensively covers universal off-the-shelf NK cells, spatial single-cell technologies, Exosome 2.0 clinical translation, and standardized practices in stem cell therapy. We invite global biotech enterprises, researchers, and clinical experts to explore underlying technological breakthroughs and accelerate the commercialization of innovative therapies.
👆Scan the QR code to contact the organizer
Register for Visiting or Click Here
Conference Room 2 Agenda
Nov 19 Morning | Forum on Innovative Cell Therapies and Clinical Applications
| Time | Topic | Speaker | Affiliation |
|---|---|---|---|
| 10:00-10:20 | The Arrival of the Era of Comprehensive Cancer Immunotherapy | Zhang Minghui | Head of Cell Therapy Research Lab, School of Basic Medical Sciences, Tsinghua University |
| 10:20-10:45 | The Role of Stem Cell Technology in Regenerative and Longevity Medicine | Han Zhongchao | Director, National Engineering Research Center of Cell Products; Academician, French Academy of Technologies; Chairman, Health & Biotech Group |
| 10:45-11:05 | Interpretation of Latest Cell Therapy Policies and Equipment Strategy Discussion | Li Dongjun | Chutian Siweikang Gene Technology (Changsha) Co., Ltd. |
| 11:05-11:25 | Application of Universal Off-the-Shelf NK Cells in Clinical Tumor Treatment and Prognosis Management | Chen Jianfeng | CMO, Yingbairui (Hangzhou) Biopharma Co., Ltd. |
| 11:25-11:45 | Breakthrough Strategies in Underlying Cell Technology | Yang Hongwei | Chief Cell Health Expert, Shanghai Cell Therapy Group |
| 11:45-12:05 | Next-Generation Autologous Adoptive Immune Cell Technology 3.0 for Advanced Solid Tumors | Shan Fengping | Chief Scientist, Shenyang Shengjing Biological Cell R&D Center Co., Ltd. |
Nov 19 Afternoon | Forum on Cell Therapy and Regenerative Medicine
| Time | Topic | Speaker | Affiliation |
|---|---|---|---|
| 14:00-14:20 | Empowering the Upgrade of the Cell Industry: Creating a New Era of Immune Microecology Health Management | Tang Bochen | President, Chengge Pharma Immune Microecology Health Management & Microbiome Experience Center |
| 14:20-14:40 | Guarding the Source of Life: Vcanbio's Cell Technology and the Future of Health | Lu Zhiping | Senior Director, Adult Cell Health Storage Dept., Vcanbio |
| 14:40-15:00 | Commercial Exploration of Longevity Medicine | Jiang Bolin | Vice President, JD Health Langjianwei Cell Therapy Hospital |
| 15:00-15:20 | Why stem cells, peptides & exosomes work and why they don’t work for many diseases, untreatable diseases and immunology. | Chen Gecheng | European Wellness BioMedical Group |
| 15:20-15:40 | iPSC Personalized Storage and Operation Solutions | Zhao Xu | GM of Marketing Center, Chengdu Yunce Medical Biotech Co., Ltd. |
| 15:40-16:00 | Application of Universal Off-the-Shelf NK Cells in Autoimmune and Aging-Related Diseases | Wang Mingqi | Medical Center Expert, Yingbairui (Hangzhou) Biopharma Co., Ltd. |
| 16:00-16:20 | New Spatial Single-Cell Technologies for Analyzing Tumor and Microenvironment Interactions | Xue Ruidong | Researcher (National Excellent Youth), Peking University First Hospital & PKU-Yunnan Baiyao International Medical Research Center |
| 16:20-16:40 | Underlying Logic and Strategy Analysis of Systematic Tumor Immunotherapy | Xie Haitao | Chairman, Guangdong Xiankangda Biotech Co., Ltd. |
Nov 20 Morning | Forum on Exosome Technology and Translational Applications
| Time | Topic | Speaker | Affiliation |
|---|---|---|---|
| 10:00-10:20 | Stem Cell and Immune Cell Technologies: Clinical Practice in Chronic Disease Management and Anti-Aging Longevity | Zheng Zhihan | General Manager, Qinhuangdao Beidaihe New District Zhongke Future Stem Cell Hospital |
| 10:20-10:40 | Vascularized Organoids for Ischemic Tissue Repair | Na Jie | Professor and Deputy Director of Aging & Regeneration Center, Tsinghua University |
| 10:40-11:00 | Global Clinical Progress of Exosomes and Functional Medicine Application Pathways | Li Zhi | General Manager, Beijing Echo Biotech Co., Ltd. |
| 11:00-11:20 | Application of Multi-Channel Nanoparticle Composite Purification System in Disease Diagnosis and Treatment | Zhu Fengqiu | Marketing Director, Shenzhen Huixin Biomedical Tech Co., Ltd. |
| 11:20-11:40 | From Raw Material Quality Control to Clinics: Standardization and Translation of Extracellular Vesicle Tech | Wei Qing | Head of Extracellular Vesicle Tech, Boyalife |
| 11:40-12:00 | Exosome 2.0: From Diagnosis to Innovative Drugs | Qi Zhen | Chief Scientist, Shanghai Nengshan Biotech Co., Ltd. |
Nov 20 Afternoon | Forum on Stem Cells and Regenerative Medicine
| Time | Topic | Speaker | Affiliation |
|---|---|---|---|
| 14:00-14:20 | From "Cannot" to "Can": Treating Premature Ovarian Insufficiency via Ovarian Injection of Umbilical Cord Mesenchymal Stem Cells | Hu Yihan | President, Ciming Boao International Hospital |
| 14:20-14:40 | Current Status of Regenerative Medicine in Japan | Ogata Shiori | Director, Ginza Bioregen Clinic |
| 14:40-15:00 | Regeneration, Anti-Aging, and Stem Cells: From Research to Application | Gu Ying | CEO, BGI Cell |
| 15:00-15:20 | Tokyo Cell Group — Leading a New Era in Stem Cell Therapy with iPS Cell Technology | Wei Zhao | Vice President, China Representative Office, Tokyo Cell Group |
| 15:20-15:40 | Key Considerations in Clinical Development of Stem Cell Products | Wang Xiujuan | Medical Director, Huayu Biotech (Tianjin) Co., Ltd. |
| 15:40-16:00 | Applied Research on Umbilical Cord Mesenchymal Stem Cell Microvesicles in Treating PD | Zhang Haiying | Chief Scientist, Youwendu Bioengineering (Shenzhen/Henan) Co., Ltd. |
